Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Lyndra Therapeutics

Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with Thermo Fisher Scientific for Long-Acting Oral Therapies
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Raises $101 Million in Series E Funding
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Presents Data on Long-Acting Oral Weekly Risperidone (LYN-005) at American Society of Clinical Psychopharmacology 2023 Annual Conference
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Announces New Board Members and Chief Technology Officer
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics’ LYNX™ Drug Delivery Platform Wins 2022 Fierce Life Sciences Innovation Award for Drug Delivery Technology
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics President and Chief Operations Officer Jessica Ballinger Named to National Small Business Association (NSBA) Leadership Council
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Doses First Clinical Trial Participant in Study of Oral Biweekly Ivermectin (LYN-163) as a Tool in the Fight to Eradicate Malaria
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Appoints Klas Holmlund, CFA, as Chief Financial Officer
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Advances Leadership in Key Roles
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics’ Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014 Granted Fast Track Designation by FDA
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other Indications
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Presents Preclinical Data on Once-Weekly Oral Buprenorphine Treatment, LYN-013, in Development for Opioid Use Disorder
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Completes $60.5 Million Series C Financing
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Receives FDA Clearance of Investigational New Drug Application for LYN-014, its Once-Weekly Oral Levomethadone Treatment in Development for Opioid Use Disorder
From Lyndra Therapeutics
Via Business Wire
Lyndra Therapeutics Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone Treatment, LYN-005, in Development for Schizophrenia
From Lyndra Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.